Health And Beauty Benefits Of Cinnamon, A New Report On, Reveals To People Simple And Easy Ways To Use Cinnamon Moderately

Seattle, Wa (PRWEB) April 24, 2014

Health And Beauty Benefits Of Cinnamon, a new report created by Rodney Hammond on the site, shows benefits of cinnamon on health and beauty, and detailed instructions on how to use it properly. In the first part of this report, people will discover some reasons to use cinnamon such as:

NuMale Medical Center Expands in Wisconsin with New Green Bay Facility Offering a Science-Based Approach to Mens Health

Green Bay, WI (PRWEB) October 27, 2014

NuMale Medical Center announced the opening of a new facility in Green Bay today. This is NuMales second office in Wisconsin and seventh nationwide; the company launched in Milwaukee and rapidly expanded to other states as demand for its unique services surged.

Like all of NuMales state-of-the-art clinics, the Green Bay location will embody the companys commitment to employing a safe, comprehensive approach to treating issues facing men of all ages and backgrounds. Since its founding in 2013, NuMale Medical Center has helped tens of thousands of men suffering from sexual dysfunction and aging-related conditions.

Led by Chief Medical Officer Dr. Christopher Asandra, M.D., NuMales expert physicians provide each patient with a comprehensive, confidential medical evaluation and consultation on their first visit. After this evaluation, NuMales medical team customizes the most appropriate and effective treatment plan to address each patients individual needs.

NuMale Medical Centers industry-leading doctors help patients suffering from erectile dysfunction (E.D.), premature ejaculation, and low sex drive. Using FDA-approved treatments, NuMales doctors achieve a 98 percent success rate in treating E.D. By employing innovative and effective treatment methods, including the Priapus (TM) procedure, NuMale is able to offer a 100 percent money back guarantee on its E.D. consultation for new patients.

NuMale is also the first and only clinic in Wisconsin to offer NeoGraft

Erectile Dysfunction Drugs Market to Sink to USD 3.4 Billion by 2019: Transparency Market Research

Albany, New York (PRWEB) September 24, 2014

The global erectile dysfunction drugs market was worth $ 4.3 billion in 2012. It is expected to decline at an aggregate rate of 4.5% between 2013 and 2019, which means the market will be valued at $ 3.4 billion in 2019.

All facts and figures have be provided through a research report titled Erectile Dysfunction Drugs Market (Viagra, Cialis, Levitra/Staxyn, Stendra/Spedra, Zydena, MUSE, Mvix and Helleva) – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 2019, published by Transparency Market Research.

To browse through the research report, or to view the ToC, please visit:

The report showed that Viagra (sildenafil citrate) by Pfizer held 45% of the global erectile dysfunction drugs market in 2012. Its majority hold over the market is predicted to decline after patent exclusivity rights expire in 2013 in Europe and other countries. Cialis (tadalafil) held the second-largest market share with $ 1.9 billion in 2012. Its patent exclusivity will reportedly expire in 2017, supplementing the decline of the erectile dysfunction drugs market by 2019. The same is to be expected from Levitra/Staxyn (Vardenafil) by Bayer, whose patent exclusivity is set to expire in 2018. The report explains that once the patents expire, the market will be flooded with competitive generic drugs with similar chemical compositions, reducing the revenue generated by the major players in the market.

Factors that might improve the growth of the erectile dysfunction drugs market are the approval of the new promising drugs Zydena (udenafil) and Stendra/Spedra (avanafil) in mid 2014.

The report categorized the global erectile dysfunction market according to the product brands or pipeline analysis. By products, the report investigates Viagra, Cialis, Levitra/Staxyn, MUSE, Zydena, Mvix, and Helleva. By pipeline analysis, the report identifies Vitaros, Uprima, Gene therapy, Melanocortin Activators, and Topiglan.

For further inquiries, ask here:

By geography, the research report identifies the regions of North America, Europe, Asia-Pacific, and Rest of the World. The North American region dominated the global erectile dysfunction drug market in revenue created. It is expected to maintain its dominance throughout the forecast period.

The key players explained in the report are Pfizer, GlaxoSmithKline, Bayer, Dong-A Pharmaceutical Corporation Limited, Eli Lilly And Company, Cristalia Produtos Quimicos Farmaceuticos Ltda., Vivus Incorporated, S.K. Chemicals Corporation Limited, Meda Pharmaceuticals, and Apricus Biosciences, Incorporated.

Erectile dysfunction is a male inability to generate and/or maintain penile erection, for the sake of a fully successful sexual intercourse. It primarily affects men above the age of 40. Typical causes of erectile dysfunction are diabetes and hypertension, along with a host of common habits attributed to a sedentary lifestyle, obesity, excessive consumption of alcohol, smoking, use of recreational drugs, and use of anti-depressants.


Sheela AK

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA/Canada Toll Free: 866-552-3453

Email: sales(at)transparencymarketresearch(dot)com


Find More Erectile Dysfunction Press Releases